Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Signs on Four Payors

NEW YORK (GenomeWeb News) – Response Genetics today said it has signed agreements with four payors to provide access to the molecular diagnostic firm's tests.

The deals are with America's Choice Provider Network, FedMed, Galaxy Health Network, and Prime Health Services, and increases the number of people in the US who now have access to Response's tests by 54 million, the company said. It added that in 2013, it has entered into a total of six PPO network contracts providing access to its tests to more than 135 million Americans.

Los Angeles-based Response offers genomic testing focused on lung, colon, and gastric cancer, as well as melanoma. The tests are used by physicians to help guide them in choosing therapeutic treatments for their patients.

Last week, the company reported that revenues in its third quarter decreased 24 percent year over year to $4.1 million.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.